

IN THE CLAIMS:

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

1. (Currently amended) A method of ~~combination therapy for treatment of~~ treating a subject diagnosed as having Fabry disease comprising administering a therapeutically effective amount of a ~~combination therapy selected from two or more of the following: an exogenously produced natural or recombinant lysosomal hydrolase enzyme replacement therapy, a gene therapy vector encoding a lysosomal hydrolase,~~ and a small molecule ~~therapy~~ such that the Fabry disease is treated.

2. (Withdrawn) The method according to claim 1 wherein the combination therapy comprises alternating between administration of an enzyme replacement therapy and a small molecule therapy.

3. (Withdrawn) The method according to claim 1 wherein the combination therapy comprises simultaneously administering an enzyme replacement therapy and a small molecule therapy.

4. (Currently amended) The method according to claim 1 wherein the combination therapy comprises administering a gene therapy vector encoding a lysosomal hydrolase and a ~~therapy selected from the group consisting of one of the following: an exogenously produced natural or recombinant lysosomal hydrolase enzyme replacement therapy and a~~ small molecule ~~therapy.~~

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

5. (Currently amended) The method according to claim 1 wherein the ~~combination therapy~~ method of treating a subject diagnosed as having Fabry disease produces a diminution in globotriaosylceramide.

6. (Currently amended) The method according to claim 1 wherein the ~~enzyme replacement therapy provides an effective amount of~~ exogenously produced natural or recombinant lysosomal hydrolase is α -galactosidase A.

7. (Withdrawn) The method according to claim 1 wherein the small molecule therapy comprises administering to the subject an effective amount of deoxynojirimycin or a deoxynojirimycin derivative.

8. (Withdrawn) The method according to claim 7, wherein the deoxynojirimycin derivative is N butyldeoxynojirimycin (NB-DNJ) or N-(5-adamantane-1-yl-methoxy)pentyl)-deoxynojirimycin (AMP-DNJ).

9. (Withdrawn) The method according to claim 1, wherein the small molecule therapy comprises administering to the subject an effective amount of a D-*threo*-1-phenyl-2-palmitoylamino-3-pyrrolidino-1-propanol (P4) derivative.

10. (Withdrawn) The method according to claim 9, wherein the P4 derivative is D-*threo*-1-(3',4'-ethylenedioxy)phenyl-2-palmitoylamino-3-pyrrolidino-1-propanol (D-t-et-P4).

11. (Withdrawn) The method according to claim 1, wherein Fabry disease has at least one central nervous system manifestation and the small molecule therapy comprises AMP-DNJ.

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

12. (New) The method according to claim 1, comprising administering a therapeutically effective amount of an exogenously produced natural or recombinant lysosomal hydrolase and a small molecule such that the Fabry disease is treated.

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com